VLST expands into oncology with clinical-stage Pfizer antibody
This article was originally published in Scrip
The private US biotechnology firm VLST has added oncology to its list of targeted disease areas, on top of autoimmune and inflammatory disorders, by in-licensing the anti-CD40 monoclonal antibody CP-870,893 from Pfizer, which has taken a 5% equity position in VLST and is entitled to milestone payments from the development programme.
You may also be interested in...
Organizations like BARDA, CEPI and others are looking to partner with industry to rapidly test, manufacture, package and deploy vaccines and therapeutics, identifying areas they want to work together during BIO’s recent summit.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
Flagship Pioneering raised $1.1bn to fund life science companies emerging from Flagship Labs. ARCH, another frequent start-up co-founder, raised two funds totaling $1.46bn to back early-stage biotech.